Prosecution Insights
Last updated: April 19, 2026
Application No. 18/027,045

MONITORING AND CONTROL OF BIOPROCESSES

Non-Final OA §112
Filed
Mar 17, 2023
Examiner
EDWARDS, LYDIA E
Art Unit
1796
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Sartorius Stedim Data Analytics AB
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
3y 9m
To Grant
64%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
419 granted / 700 resolved
-5.1% vs TC avg
Minimal +4% lift
Without
With
+4.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
36 currently pending
Career history
736
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
49.1%
+9.1% vs TC avg
§102
20.6%
-19.4% vs TC avg
§112
22.3%
-17.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 700 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) submitted on 03/17/2023 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-13 and 17-20 in the reply filed on 11/03/2025 is acknowledged. Claims 15-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 11/03/2025. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 4, 10-12 and 17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 4 recites the limitation “the cellular compartment” in line 4 and “the culture medium compartment” in line 5. There is insufficient antecedent basis for this limitation in the claim. Regarding claim 10, the phrase similar renders the claim indefinite because it is unclear what applicant intended to cover by the recitation “similar”. See MPEP § 2173.05(b). Claim 12 recites the limitation “the plurality of runs” in lines 1-2 and “the plurality of training runs” in line 5. There is insufficient antecedent basis for this limitation in the claim. Claims 11 and 17 are dependent on claim 10 and are therefore, rejected for the same reason. Allowable Subject Matter Claims 1-3, 5-9, 13 and 18-20 are allowed. The following is a statement of reasons for the indication of allowable subject matter: The closets prior art of record is GAO JINXIN ET AL: "Multivariate analysis of cell culture bioprocess data", AMERICAN PHARMACEUTICAL REVIEW, vol. 23, no. 3, 1 April 2020 (2020-04-01), pages 78-81 and Wolfgang et al. WO 2019/129891 A1 (cited in the IDS filed 03/17/2023). Gao teaches obtaining measurements, using a pre-trained multivariate model to determine the value of one or more latent variables, comparing the values of the one or more latent variables to one or more predetermined values as a function of maturity and determining on the basis of the comparison whether the bioprocess is operating normally. Gao does not suggest determining one or more metabolic condition variables and using the metabolic variable conditions as predictor variables to monitor the current state of a bioprocess. Wolfgang et al. uses predicted future metabolic states as indications of the state of the bioprocess, which provides a different approach to bioprocess monitoring than Gao and the instant invention. The international search report, opposition decision and the references cited therein were fully reviewed. The prior art fails to teach or suggest the instant claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LYDIA EDWARDS whose telephone number is (571)270-3242. The examiner can normally be reached on Monday-Thursday 6:30-5:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Curtis Mayes can be reached on 571-272-1234. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LYDIA EDWARDS/Primary Examiner, Art Unit 1796
Read full office action

Prosecution Timeline

Mar 17, 2023
Application Filed
Feb 21, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12569807
METHOD FOR SIMULTANEOUSLY REMOVING HIGH-LOAD SULFUR DIOXIDE AND NITROGEN OXIDE IN WASTE GAS
2y 5m to grant Granted Mar 10, 2026
Patent 12545879
BIOPROCESS DEVICE ASSEMBLY AND INOCULATION METHOD
2y 5m to grant Granted Feb 10, 2026
Patent 12545877
SYSTEMS AND METHODS FOR CELL CULTURING
2y 5m to grant Granted Feb 10, 2026
Patent 12532881
TISSUE PACKAGING AND METHOD OF USING SAME
2y 5m to grant Granted Jan 27, 2026
Patent 12529022
HUMAN ORGAN-ON-CHIP MODELS FOR PREDICTIVE SCREENING
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
64%
With Interview (+4.1%)
3y 9m
Median Time to Grant
Low
PTA Risk
Based on 700 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month